Barclays PLC cut its stake in BiomX Inc. (NYSEMKT:PHGE – Free Report) by 90.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the company’s stock after selling 225,000 shares during the period. Barclays PLC owned approximately 0.14% of BiomX worth $26,000 at the end of the most recent quarter.
Separately, Ikarian Capital LLC acquired a new stake in shares of BiomX during the 3rd quarter worth approximately $911,000. 40.57% of the stock is currently owned by hedge funds and other institutional investors.
BiomX Stock Up 11.0 %
BiomX stock opened at $0.82 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The company has a market capitalization of $14.91 million, a PE ratio of -1.09 and a beta of 1.26. The company has a 50-day simple moving average of $0.66 and a 200-day simple moving average of $1.16.
About BiomX
BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
Further Reading
- Five stocks we like better than BiomX
- Using the MarketBeat Dividend Yield Calculator
- Bloom Energy: Powering the Future With Decentralized Energy
- What Are Growth Stocks and Investing in Them
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- What is a buyback in stocks? A comprehensive guide for investors
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
